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Dear Editor,
Allogeneic hematopoietic stem cell transplantation
(allo-HSCT) has been considered as standard therapy
for aggressive adult T cell leukemia/lymphoma (ATLL)
patients to achieve a long-term survival [1, 2]. Anti-
CCR4 monoclonal antibody mogamulizumab (Mog) is
the first immunotherapeutic agent targeting ATLL. Since
CCR4 is expressed on regulatory T cells (Treg), there is
growing concern regarding increased risk of severe and
refractory acute graft-versus-host disease (aGVHD) in
ATLL patients treated with Mog before allo-HSCT
(pretransplant Mog) [3–6].
We describe a case of an acute-type ATLL patient who
underwent HLA-haploidentical peripheral blood stem cell
transplantation (haplo-PBSCT) following pretransplant Mog.
The interval between the last Mog administration and haplo-
PBSCT was 49 days. A 65-year-old Japanese male pre-
sented with a 2-week history of fatigue, anorexia, and
nausea. He was diagnosed as acute-type ATLL with hy-
percalcemia. His ATLL including abnormal bone lesions
was chemorefractory. Therefore, he was further treated
with two doses of Mog (1 mg/kg weekly for 2 weeks).
The disease status significantly improved after Mog ad-
ministration. Unmanipulated haplo-PBSCT was per-
formed from his son (Table 1). The conditioning consisted
of fludarabine (25 mg/m2/day, days −8 to −4), melphalan
(80 mg/m2, day −3), rabbit anti-thymocyte globulin
(thymoglobulin; 2.5 mg/kg, day −2), and TBI (4 Gy).
Tacrolimus and mycophenolate mofetil were further
used for GVHD prophylaxis. Stable and complete do-
nor chimerism was obtained. On day 30, he only de-
veloped grade I aGVHD (stage 1 skin rash). One year
later, the number of CD4 + CD25 + CD127-/low Treg
cells and CD4 + T cells in his PB remained below the
normal range (15/μL and 183/μL, respectively), show-
ing delayed T cell reconstitution. He has been in com-
plete remission (CR) without chronic GVHD for
2 years.
Low-dose thymoglobulin, in addition to its T cell
depleting properties, stimulates the recovery of Treg
cells [7, 8]. In this regard, Motohashi et al. reported
an acute-type ATLL patient who achieved CR following
Mog treatment and subsequently received unrelated
bone marrow transplantation (uBMT) [9]. Two months
after the last Mog administration, uBMT was performed
from a serologically two antigen (HLA-C and -DR) mis-
matched donor by using conditioning with 1.25 mg/kg
of thymoglobulin. As a result, they only observed grade
I aGVHD.
In ATLL, allo-HSCT at disease regression induced by ini-
tial treatment has been shown to improve the clinical outcome
[10]. Pretransplant Mog significantly improved the disease
status before haplo-PBSCT. Moreover, a recent nationwide
study of ATLL patients with pretransplant Mog in Japan
showed that pretransplant Mog with intervals of <50 days to
allo-HSCT was associated with increased risk of GVHD-
related mortality [6]. In our case, the interval between
pretransplant Mog and haplo-PBSCT was 49 days. The na-
tionwide study also pointed out the possibility that in vivo
effector T cell depletion with anti-thymocyte globulin contrib-
utes to the reduction of severe aGVHD in ATLL patients with
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pretransplant Mog [6]. To our knowledge, our case is the
first report of successful prevention of aGVHD with low-
dose thymoglobul in in haplo-PBSCT fol lowing
pretransplant Mog. Low-dose thymoglobulin is an effec-
tive option for aGVHD prophylaxis in ATLL patients
with pretransplant Mog.
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Table 1 HLA status of the patient and donor
Sex Relation Blood type HLA-A HLA-B HLA-C HLA-DR
Recipient Male A+ 0201/2402 3901/5502 0702/0102 1201/0901
Donor Male Son A+ 0201/0206 3901/5101 0702/1402 1201/0803
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